Pediatric Metabolic Alkalosis 

  • Author: Lennox H Huang, MD; Chief Editor: Timothy E Corden, MD   more...
 
Updated: Jun 8, 2011
 

Background

Metabolic alkalosis is an acid-base disturbance caused by an elevation in the plasma bicarbonate (HCO3) concentration. This condition is not a disease; it is a sign or state encountered in certain disease processes. Although metabolic alkalosis may not be referred to as often as metabolic acidosis, it is the most common acid-base abnormality in hospitalized adults. Alkalosis refers to a loss of acid or gain of base in the extracellular fluid (ECF); alkalemia refers to a change in blood pH. Alkalosis is not necessarily accompanied by alkalemia.

The 2 types of metabolic alkalosis (ie, chloride-responsive, chloride-resistant) are classified based on the amount of chloride in the urine.

Chloride-responsive metabolic alkalosis involves urine chloride levels of less than 10 mEq/L and is characterized by decreased ECF volume and low serum chloride levels, such as occurs with vomiting. This type responds to administration of chloride salt.

Chloride-resistant metabolic alkalosis involves urine chloride levels of more than 20 mEq/L and is characterized by increased ECF volume. As the name implies, this type resists administration of chloride salt. Primary aldosteronism is an example of chloride-resistant metabolic alkalosis.

For a review of metabolic alkalosis in patients of all ages, see Metabolic Alkalosis.

Next

Pathophysiology

Causes of metabolic alkalosis include (1) loss of hydrogen ions (eg, due to vomiting or renal acid losses that exceed acid production from cellular metabolism), (2) disproportionate chloride loss compared with HCO3 loss (ie, the plasma concentration of HCO3 increases upon restriction to a smaller space of distribution), and (3) HCO3 administration (unusual because additional HCO3 is very quickly eliminated by the kidneys). Loss of hydrochloric acid due to vomiting is an especially common cause.

The consequences of metabolic alkalosis on organ systems depend on the severity of the alkalemia and the degree of respiratory compensation. Mild-to-moderate metabolic alkalosis is rarely clinically significant in isolation. If the elevated plasma HCO3 concentration is not accompanied by a rise in PCO2, the elevation of pH is much more severe.

Effects of severe alkalemia

The respiratory effects of metabolic alkalosis are twofold. An increase in blood pH shifts the oxygen-hemoglobin dissociation curve to the left. This creates a tighter bond between hemoglobin and oxygen, causing decreased oxygen delivery to tissues. Hypoxemia may be worsened by a compensatory hypoventilation to elevate PCO2. Hypoventilation may be severe enough to cause apnea and respiratory arrest.

Cardiovascular effects often result from the association of hypokalemia with metabolic alkalosis. Life-threatening arrhythmias are the most significant adverse effect of metabolic alkalosis. Direct arteriolar constriction is further worsened by electrolyte disturbances. Ventricular and supraventricular arrhythmias that are often unresponsive to antiarrhythmic agents can occur.

Neuromuscular effects of severe metabolic alkalosis may include headache, seizures, and obtundation and marked muscle weakness. These resolve only with correction of the pH.

Electrolyte imbalances in metabolic alkalosis include a decrease in ionized calcium levels due to increased binding of calcium to plasma proteins; consequences include tetany and seizures. Total-body potassium loss may contribute to alkalemia, and serum potassium is intracellularly shifted in alkalemia. Weakness and cardiac arrhythmias may result from severe hypokalemia.

Compensation mechanisms

The body compensates for metabolic alkalosis through buffering of excess HCO3 and hypoventilation. Intracellular buffering occurs through sodium/hydrogen and potassium/hydrogen ion exchange, with eventual formation of CO2 and water from HCO3.

Within several hours, elevated levels of HCO3 and metabolic alkalosis stimulate a chemoreceptor inhibition of the respiratory center, resulting in hypoventilation and increased PCO2 levels. This mechanism produces a rise in PCO2 of as much as 0.7 mm Hg for each 1-mEq/L increase in HCO3. Hypoventilation may cause hypoxemia.

Previous
Next

Etiology

Etiologically, metabolic alkalosis can be divided into chloride-responsive alkalosis (urine chloride < 20 mEq/L), chloride-resistant alkalosis (urine chloride >20 mEq/L). Causes of chloride-responsive metabolic alkalosis include the following:

  • Gastric fluid loss (eg, vomiting, nasogastric [NG] drainage)
  • Volume contraction (eg, secondary to loop or thiazide diuretics)
  • Congenital chloride diarrhea
  • Posthypercapnia syndrome (especially in mechanically ventilated patients with chronic lung disease)
  • Cystic fibrosis (in toddlers)

Causes of chloride-resistant metabolic alkalosis include the following:

  • Primary aldosteronism
  • Bartter syndrome (renal sodium, potassium, and chloride wasting; often presents as failure to thrive)[1]
  • Deoxycorticosterone (DOC) excess syndrome (congenital adrenal hyperplasia variant)
  • Liddle syndrome (autosomal dominant; unregulated sodium resorption in renal collecting duct)
  • Excessive ingestion of licorice
  • Chronic potassium depletion (eg, anorexia nervosa)
  • Primary reninism
  • Hyperglucocorticoidism
  • Milk-alkali syndrome (excess calcium plus bicarbonate intake and vomiting)

Regarding gastric losses (eg, vomiting, NG drainage), HCO3 produced by the pancreas normally neutralizes HCl produced by the gastric mucosa, so that no net gain or loss of hydrogen ions or bicarbonate occurs. When gastric acid is lost through vomiting or removed by suction, plasma HCO3 levels increase. In addition, the loss of potassium and volume contraction due to vomiting potentiate metabolic alkalosis.

Diuretics produce increased renal losses of sodium, which is followed by excretion of chlorides. To maintain electrical neutrality in the ECF, HCO3 reabsorption in renal tubules increases. Additionally, increased sodium in the distal tubules increases sodium-potassium exchange. The loss of potassium, in turn, leads to intracellular accumulation of hydrogen ions and its secretion in the distal tubules. Diuretics also promote the loss of magnesium in the urine, which further lowers potassium levels through an unknown mechanism.

Volume contraction concentrates the existing levels of HCO3 in the ECF. In addition, it stimulates release of renin-angiotensin, which causes increased potassium and hydrogen ion losses in the kidney.

Regarding posthypercapnia syndrome, chronic CO2 retention causes a compensatory increase in HCO3 levels. When a patient with chronic CO2 retention receives treatment that abruptly drops the CO2 level, metabolic alkalosis becomes evident.

Previous
Next

Epidemiology

Because metabolic alkalosis is a manifestation of a disease process rather than a disease itself, the incidence is unknown. In a review of 2000 hospitalized adults, Hodgkin et al noted that metabolic alkalosis was the most common acid-base disorder.[2] No racial or sexual differences in incidence are noted.

Metabolic alkalosis can occur in people of any age. A higher incidence of metabolic alkalosis after cardiac surgery in younger children has been reported, however.[3]

Previous
Next

Prognosis

The overall prognosis in patients with metabolic alkalosis depends on the underlying etiology. Chloride-responsive metabolic alkalosis responds to volume resuscitation and chloride repletion. Chloride-resistant metabolic alkalosis may be more difficult to control. Prognosis is good with prompt treatment and avoidance of hypoxemia.

Severe metabolic alkalosis is associated with increased morbidity and mortality, probably because of its profound influences on multiple organ systems and, more importantly, because of tissue anoxia caused by hypoventilation and shift of the oxygen-dissociation curve to the left.[4]

Previous
Next

Patient Education

Educate patients placed on long-term diuretic therapy and those with diseases that can lead to metabolic alkalosis to recognize the symptoms of moderate-to-severe alkalosis. This knowledge allows them to promptly seek medical care.

Previous
 
 
Contributor Information and Disclosures
Author

Lennox H Huang, MD  Chair, Department of Pediatrics, McMaster University School of Medicine; Chief of Pediatrics, McMaster Children's Hospital

Lennox H Huang, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Physician Executives, Canadian Medical Association, Ontario Medical Association, and Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Coauthor(s)

Margaret A Priestley, MD  Assistant Professor of Clinical Anesthesiology and Critical Care, University of Pennsylvania School of Medicine; Clinical Director, Pediatric Intensive Care Unit, The Children's Hospital of Philadelphia

Margaret A Priestley, MD is a member of the following medical societies: American Academy of Pediatrics, American Medical Association, and Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Specialty Editor Board

G Patricia Cantwell, MD, FCCM  Professor of Clinical Pediatrics, University of Miami, Leonard M Miller School of Medicine; Chief, Division of Pediatric Critical Care Medicine, Medical Manager, Urban Search & Rescue, South Florida TF-2, Medical Director, Holtz Children's Hospital Palliative Care Team, Medical Director, Tilli Kids – Pediatric Initiative of Hospice Care of SE Florida, Director, Pediatric Critical Care Transport, Holtz Children's Hospital/Jackson Memorial Hospital

G Patricia Cantwell, MD, FCCM is a member of the following medical societies: American Academy of Hospice and Palliative Medicine, American Academy of Pediatrics, American Heart Association, American Trauma Society, National Association of EMS Physicians, Society of Critical Care Medicine, and Wilderness Medical Society

Disclosure: Nothing to disclose.

Mary L Windle, PharmD  Adjunct Associate Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Nothing to disclose.

Barry J Evans, MD  Assistant Professor of Pediatrics, Temple University Medical School; Director of Pediatric Critical Care and Pulmonology, Associate Chair for Pediatric Education, Temple University Children's Medical Center

Barry J Evans, MD is a member of the following medical societies: American Academy of Pediatrics, American College of Chest Physicians, American Thoracic Society, and Society of Critical Care Medicine

Disclosure: Nothing to disclose.

Chief Editor

Timothy E Corden, MD  Associate Professor of Pediatrics, Co-Director, Policy Core, Injury Research Center, Medical College of Wisconsin; Associate Director, PICU, Children's Hospital of Wisconsin

Timothy E Corden, MD is a member of the following medical societies: American Academy of Pediatrics, Phi Beta Kappa, Society of Critical Care Medicine, and Wisconsin Medical Society

Disclosure: Nothing to disclose.

References
  1. Caltik A, Akyuz SG, Erdogan O, Bulbul M, Demircin G. Rare presentation of cystinosis mimicking Bartter's syndrome: reports of two patients and review of the literature. Ren Fail. Jan 2010;32(2):277-80. [Medline].

  2. Hodgkin JE, Soeprono FF, Chan DM. Incidence of metabolic alkalemia in hospitalized patients. Crit Care Med. Dec 1980;8(12):725-8. [Medline].

  3. van Thiel RJ, Koopman SR, Takkenberg JJ, Ten Harkel AD, Bogers AJ. Metabolic alkalosis after pediatric cardiac surgery. Eur J Cardiothorac Surg. Aug 2005;28(2):229-33. [Medline].

  4. Anderson LE, Henrich WL. Alkalemia-associated morbidity and mortality in medical and surgical patients. South Med J. Jun 1987;80(6):729-33. [Medline].

  5. Buchanan IB, Campbell BT, Peck MD, Cairns BA. Chest wall necrosis and death secondary to hydrochloric acid infusion for metabolic alkalosis. South Med J. Aug 2005;98(8):822-4. [Medline].

  6. Moviat M, Pickkers P, van der Voort PH, van der Hoeven JG. Acetazolamide-mediated decrease in strong ion difference accounts for the correction of metabolic alkalosis in critically ill patients. Crit Care. Feb 2006;10(1):R14. [Medline].

  7. Moffett BS, Moffett TI, Dickerson HA. Acetazolamide therapy for hypochloremic metabolic alkalosis in pediatric patients with heart disease. Am J Ther. Jul-Aug 2007;14(4):331-5. [Medline].

Previous
Next
 
Algorithm for metabolic alkalosis.
 
 
 
All material on this website is protected by copyright, Copyright © 1994-2012 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.